In patients with ulcerative colitis who fail corticosteroids and are treated with rescue therapy (e.g. infl iximab or cyclosporine) but fail to respond, salvage therapy with infl iximab or cyclosporine can be considered. We sought to assess the effi cacy and safety of this third-line salvage therapy.
Introduction
Ulcerative colitis (UC) is a chronic idiopathic infl ammatory bowel disease that can be associated with severe fl ares requiring hospitalizations in up to 25% of patients [1] . While the majority of patients admitted with severe UC will respond to intravenous steroids, one-third will require rescue therapy with infl iximab, cyclosporine, or colectomy [2] .
Cyclosporine has been shown to be eff ective in 64-82% of patients with UC failing intravenous corticosteroids [3, 4] . Infl iximab was later shown to be eff ective in this situation with similar effi cacy [5] . Recently, a randomized controlled trial of infl iximab versus cyclosporine for rescue therapy found response rates of approximately 85% at 7 days, and sustained response of 40-50% with either drug three months later [6] . Nevertheless, a substantial number of patients fail rescue medical therapy. Many would argue that in this situation colectomy is the appropriate choice, but some patients wish to avoid surgery. Th ere are a number of studies that have assessed the effi cacy and safety of salvage therapy with infl iximab or cyclosporine following the failure of the other medication. However, these studies are small and none are randomized trials to assess the true effi cacy of this therapy [7] [8] [9] [10] [11] . Th e most recent UC guidelines from the European Crohn's and Colitis Organisation (ECCO) state that using salvage therapy with a third drug is associated with signifi cant risks but this can be considered in highly selected cases and only in special referral centers [12] .
Given the limited data regarding the effi cacy and safety of third-line salvage therapy following initial treatment with either infl iximab or cyclosporine for intravenous steroid-refractory UC, we sought to perform a systematic review and metaanalysis of the studies evaluating this situation with the primary outcomes of clinical remission and serious adverse events.
Materials and methods
We performed an online search using PubMed (National Center for Biotechnology Information) to identify papers published between 1960 and 2015 using infl iximab or cyclosporine as third-line salvage therapy in patients with UC who failed intravenous corticosteroids and rescue therapy with infl iximab or cyclosporine. Our search on PubMed was performed on January 1, 2015 with the following Mesh and text terms:
( Th is search resulted in 30 manuscripts. Each manuscript was reviewed to determine if the therapy involved was consistent with our study regarding third-line salvage therapy.
Inclusion criteria
Any article published and indexed on PubMed that assessed the use of infl iximab or cyclosporine as third-line salvage therapy following the initial failure of intravenous corticosteroids and either infl iximab or cyclosporine. In order to be included, the use of the third-line agent had to be within 60 days of cessation of the prior drug.
Exclusion criteria
Articles not indexed on PubMed were excluded. Abstracts only presented at a medical conference but not published as a manuscript were not included. Additionally, case reports of only a single patient and review articles were also excluded.
Outcomes
Our primary outcomes were clinical remission and serious adverse events associated with each drug and in aggregate. Secondary outcomes included clinical response and 12 month colectomy rates.
Data extraction
Articles were reviewed independently by two authors (JDF, MA) for publication date, type of salvage therapy (infl iximab, cyclosporine) number of patients, response, remission, failure/ colectomy, and any complications. Clinical remission was defi ned as normalization of bowel movement to <4/day without bleeding and off corticosteroids. Serious adverse events were infection or death.
Quality assessment
Given the few studies that were available on this topic, all studies were included.
Statistical analysis
Pooled estimates of primary and secondary outcome response rates for third-line salvage therapy were calculated using the random eff ects model. Similarly, the random eff ects model was used to calculate pooled odds ratio and 95% confi dence intervals (CI) for studies that compared outcomes between the two third-line salvage therapies. Heterogeneity was assessed by the Q and I 2 statistics. All analysis was performed using STATA (Version 12.0; STATA Corporation, College Station, TX, US).
Results
Our PubMed search yielded 40 articles of which 5 specifi cally evaluated third-line salvage therapy in severe refractory hospitalized UC ( Fig. 1 ) [7] [8] [9] [10] [11] . One manuscript was a case report of a single patient and therefore excluded from further analysis [8] . Th e remaining four articles included patients treated with infl iximab following failure of cyclosporine [7, [9] [10] [11] . However, only two of the articles, Maser et al and Leblanc et al, also included patients who were switched to cyclosporine aft er failing infl iximab [9, 10] . Th ere were 138 patients who received infl iximab and 30 patients treated with cyclosporine as a third-line salvage therapy. In each of the studies, patients were retrospectively evaluated from 2000-2008. Maser et al was a single-center US study whereas the other studies were multi-center studies performed in Europe. All the studies were designed retrospectively. See Table 1 for full demographics of the study populations.
Infl iximab following cyclosporine as third-line salvage therapy
In the studies assessing salvage therapy with infl iximab following cyclosporine usage, the mean age of the patients was 35 and 41% (57/138) were female. Th e average duration of disease was 3.8 years. However, the European studies had a mean disease duration of 2.2 years compared to 8.6 in the United States study. Sixty-six percent of patients (91/138) had extensive colitis and 49% (67/138) were previously or concomitantly on a thiopurine or methotrexate. Th ere was a mean of 11 days (range 2-19) between the last dose of cyclosporine and the initial dose of infl iximab.
Th e pooled clinical response and remission event rate for infl iximab as third-line salvage therapy was 68% (95%CI 57-79%) and 41% (95%CI 24-58%) respectively at 3 months. Th e 12-month colectomy event rate was 41% (95%CI 27-55%) (Fig. 2) .
Of the 138 patients in these studies, when assessed in aggregate, 3 patients died (2.2%) and 14 patients (10.1%) developed an infectious complication during the study period (Table 2 ). Other complications included leukopenia, infusion reaction, skin rash, renal abnormalities, and small bowel obstruction. Th e serious adverse event rate was 9% (95% CI 4-14%), while the overall adverse event rate was 21% (95%CI 14-28%) (Fig. 2) .
Cyclosporine following infl iximab as third-line salvage therapy
In the two studies assessing salvage therapy with cyclosporine following infl iximab therapy the mean age of the patients was 42 and 43% (13/30) of patients were female. Th e average duration of disease was 6.7 years and the majority of patients (77%, 23/30) had extensive colitis. Seventy-three percent (22/30) of patients were previously or concomitantly on a thiopurine or methotrexate. Th ere was a mean of 20 days (range 19-21) between the last dose of infl iximab and starting cyclosporine.
Th e overall response and remission event rates was 60% (95% CI 43-78%) and 18% (95%CI 4-31%) respectively at three months. Th e 12-month colectomy event rate was 57% (95%CI 39-74%) (Fig. 3) .
Th ere were no deaths among patients observed in these studies, but 10% (3/30) of all the patients developed an infectious complication (Table 2 ). Other complications included renal and hepatic abnormalities, fatigue, leg cramps, weakness, cough, and pancreatitis. Th e serious adverse event rate was 12% (95%CI 0.01-23%), and total adverse event rate was 31% (95%CI 16-47%) (Fig. 3) .
Comparison of third-line salvage therapies
Given that only two studies reported results on patients receiving salvage therapies with cyclosporine following infl iximab and infl iximab following cyclosporine the overall data was extremely limited. Meta-analysis comparing these two strategies did not demonstrate a signifi cant diff erence in achieving clinical response (RR 1.03, 95%CI 0.7-1.46; P=0.87), remission (RR 0.69, 95%CI 0.30-1.57; P=0.37), or 12-month colectomy (RR 1.14, 95%CI 0.79-1.67; P=0.48) (Fig. 4) . Similarly, there was no diff erence in serious adverse events (RR 1.18, 95%CI 0.34-4.07; P=0.80) or total adverse events (RR 1.91, 95%CI 0.38-9.64; P=0.43) (Fig. 4) . 
Discussion
Th ird-line salvage therapy with either infl iximab or cyclosporine is of great interest as approximately 60% of patients may fail initial rescue therapy following a lack of response to intravenous steroids [6] . In our meta-analysis of the literature, the choice of infl iximab or cyclosporine as a third-line agent did not provide any signifi cant diff erence in response, remission, colectomy, or adverse events. Overall, 41% of patients achieved an initial remission when using infl iximab as a third-line therapy which compared to an 18% remission rate in those using cyclosporine as a third-line agent. However, by 12 months 41% of patients treated with infl iximab and 57% of patients who received cyclosporine required colectomy. Additionally, both agents were associated with signifi cant adverse events when used as a third-line agent (9% for infl iximab and 12% for cyclosporine). While many are intrigued by the idea of third-line salvage therapy, the overall benefi ts and safety of this option remain unclear. When considering the initial use of salvage therapy in patients failing intravenous steroids, Laharie et al randomized patients to either infl iximab or cyclosporine and noted treatment failure in 54-60% of cases within 3 months [6] . Interestingly, in our study, additional salvage therapy with a third agent failed to achieve remission in 60-80% of cases. Furthermore, colectomy was still the outcome in 40-57% of the patients despite the use of a third-line therapy. Ultimately, the utility and risk benefi t analysis of using a third-line salvage therapy is unclear at this time.
Th e decision regarding a third-line salvage therapy is usually urgent with colectomy being the only other option. Given the severely active disease, the ability to allow the prior drug to washout of the patient's system is usually not feasible. In our meta-analysis, the average interval between cyclosporine to Figure 2 Pooled response, remission, colectomy and adverse events for third-line cyclosporine to infl iximab salvage therapy infl iximab was 11 days and the interval between infl iximab to cyclosporine was 20 days. Th e data regarding the effi cacy and safety of an immediate transition from one drug to the next is extremely limited. Th erefore, the generalizability of these studies to patients who were just dosed with either cyclosporine or infl iximab with a plan to salvage with a third-line drug is unclear. It is possible that the risk of serious adverse events may be even higher in this setting given the immunosuppression with corticosteroids, combined with the recently stopped immunosuppressive agent, and with the new added third-line salvage drug. Already, our study notes that the risk of serious adverse events is high even with a small washout period of 11-20 days. As a result, it is yet another reason to be extremely cautious when considering the use of third-line salvage therapy as an option. When using rescue therapy for steroid refractory UC, Laharie et al reported complication rates of 16% in patients treated with cyclosporine and 25% in those treated with infl iximab [6] . When these agents are then used as third-line salvage therapy we found a similar risk of serious adverse events of 9% with infl iximab and 12% with cyclosporine. Th ough there was no signifi cant diff erence in complications 2% of patients treated with infl iximab following cyclosporine died compared to no deaths reported in the group that received cyclosporine following infl iximab [13] . It is unclear if this is truly related to cyclosporine third-line therapy being safer or just due to the limited number of patients (n=30) given cyclosporine aft er infl iximab. What is especially concerning about the mortality associated with third-line therapy, is that this mortality rate is slightly higher than what is reported following colectomy in the setting of acute severe UC [14] . To use a drug that carries a higher rate of death compared to colectomy raises important questions regarding the safety of this option.
As new drugs become available to treat UC, it remains unclear if any will be eff ective as rescue therapy options. Currently, vedolizumab, an anti α4/β7 integrin monoclonal antibody, is the newest drug available to treat UC [15] . While its overall effi cacy in treating UC is clear, the utility of this drug in the setting of a severe fl are is unlikely to be eff ective. Th e drug works by antagonizing the integrin receptor and thereby blocking lymphocyte migration to the gastrointestinal mucosa [15, 16] . It does not however treat the active infl ammatory process quickly which is needed in cases of steroid refractory UC [16] . Ultimately, new drugs are needed that work on the active infl ammatory process to further the armamentarium from the current two drug option when failing rescue therapy.
As with any meta-analysis, our study has a number of limitations most of which are due to the nature of the studies reviewed. All the manuscripts included in our study were retrospective. Th e total number of patients in the cyclosporine salvage therapy following infl iximab was smaller and included in only two studies somewhat limiting our comparison between the groups. Additionally, the study follow up time Figure 3 Pooled response, remission, colectomy and adverse events for third-line infl iximab to cyclosporine salvage therapy period between studies was variable limiting the ability to provide response and remission rates at 12 months.
In conclusion, third-line salvage therapy with either cyclosporine or infl iximab is effi cacious in some patients but carries a signifi cant risk of complications. Importantly, 41-57% of these patients will end up requiring a colectomy within 12 months. Future studies are needed to prospectively evaluate the benefi ts and risks of this strategy compared to colectomy. 
Summary Box
What is already known:
• 25% of patients with ulcerative colitis (UC) will have a fl are requiring admission for intravenous steroids • Up to 60% of patients will fail salvage therapy in UC • Both cyclosporine and infl iximab have been tried as third-line salvage agents for UC What the new fi ndings are:
• Infl iximab and cyclosporine third-line therapy are associated with a pooled response rate of 68% and 60%, respectively • Infl iximab and cyclosporine third-line therapy are associated with a pooled remission rate of 41% and 18%, respectively • Th e 12-month colectomy rates were 41% for infl iximab and 57% for cyclosporine • Th e drugs are associated with serious adverse event rates of 9% with infl iximab and 12% with cyclosporine
